Role of drugs and devices in patients at risk of sudden cardiac death

Fundamental and Clinical Pharmacology

Volumn 24, Issue 5, 2010, Pages 575-594

  Boriani, Giuseppe ^a   Diemberger, Igor ^a   Valzania, Cinzia ^a   Biffi, Mauro ^a   Martignani, Cristian ^a   Raschi, Emanuel ^b   Mantovani, Valentina ^a   Ziacchi, Matteo ^a   Bertini, Matteo ^a   De Ponti, Fabrizio ^b   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

anti arrhythmic drugs; cardioverter defibrillator; sudden cardiac death; ventricular fibrillation

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; ENCAINIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; METOPROLOL; MEXILETINE; MORACIZINE; OMEGA 3 FATTY ACID; PERINDOPRIL; PLACEBO; RAMIPRIL; SOTALOL; TRANDOLAPRIL; UNINDEXED DRUG; ZOFENOPRIL;

AGE; BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CARDIOVERSION; CHAGAS DISEASE; CHANNELOPATHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATION; DEFIBRILLATOR; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROARRHYTHMIA; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LONG QT SYNDROME; MORBIDITY; MORTALITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH; SYNCOPE; SYSTEMATIC REVIEW; VASCULAR FIBROSIS;

ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 77957003280     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00853.x     Document Type: Review

References (123)

1. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation (1992) 85 (1 Suppl) I2 I10.
2. Billman G.E. A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: Implications for future anti-arrhythmic drug development. Pharmacol. Ther. (2006) 111 808 835.
3. Zipes D., Wellens H.J. Sudden cardiac death. Circulation (1998) 98 2334 2351.
4. Josephson M., Wellens H.J. Implantable defibrillators and sudden cardiac death. Circulation (2004) 109 2685 2691.
5. Myerburg R.J. Sudden cardiac death exploring the limits of our knowledge. J. Cardiovasc. Electrophysiol. (2001) 12 369 381.
6. Reducing the risk: a strategic approach. The report of the task force on sudden cardiac death. Published by the Department of Health and Children. Ireland (2006 1 158.
7. Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Europace (2006) 8 746 837.
8. Boriani G., Valzania C., Diemberger I. et al. Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opin. Investig. Drugs (2007) 16 605 623.
9. Members of the Sicilian Gambit: The "Sicilian Gambit." A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur. Heart J. (1991) 12 1112 1131.
10. Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J. Am. Coll. Cardiol. (1984) 4 1148 1163.
11. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. (1989) 321, 406 412.
12. Echt D., Liebson P., Mitchell B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial (CAST I). N. Engl. J. Med. (1991) 324 781 788.
13. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med. (1992) 327 227 233.
14. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA (1993) 270 1589 1595.
15. Julian D.G., Prescott R.J., Jackson F.S., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet (1982) 1 1142 1147.
16. Waldo A., Camm J., deRuyter H. et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction (SWORD: Survival With Oral D-sotalol). Lancet (1996) 348 7 12.
17. Kober L., Bloch Thomsen P., Moller M. et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356 2052 2058.
18. Camm A.J., Pratt C.M., Schwartz P.J. et al. on behalf of the AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation (2004) 109 990 996.
19. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344 493 498.
20. Singh S.N., Fletcher R.D., Fisher S.G. et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med. (1995) 333 77 82.
21. Julian D.G., Camm A.J., Frangin G. et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet (1997) 349 667 674.
22. Cairns J.A., Connolly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet (1997) 349 675 682.
23. Elizari M.V., Martinez J.M., Belziti C. et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators. Eur. Heart J. (2000) 21 198 205.
24. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet (1997) 350 1417 1424.
25. Piccini J.P., Berger J.S., O'Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur. Heart J. (2009) 30 1245 1253.
26. Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. (2005) 352 225 237.
27. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. (1997) 337, 1576 1583.
28. Connolly S.J., Gent M., Roberts R.S. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 101 1297 1302.
29. Kuck K.H., Cappato R., Siebels J., Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation (2000) 102 748 754.
30. Connolly S.J., Hallstrom A.P., Cappato R. et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur. Heart J. (2000) 21 2071 2078.
31. Moss A.J., Hall W.J., Cannom D.S. et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. (1996) 335 1933 1940.
32. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med. (1999) 341 1882 1890.
33. Moss A.J., Zareba W., Hall W.J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. (2002) 346 877 883.
34. Bristow M.R., Saxon L.A., Boehmer J. et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. (2004) 350 2140 2150.
35. Moss A.J., Hall W.J., Cannom D.S. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. (2009) 361 1329 1338.
36. Boriani G., Ricci R., Toselli T., Ferrari R., Branzi A., Santini M. Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Eur. Heart J. Suppl (2007) 9 (Suppl I) I66 I73.
37. Ezekowitz J.A., Rowe B.H., Dryden D.M. et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann. Intern. Med. (2007) 147 251 262.
38. Epstein A.E., Dimarco J.P., Ellenbogen K.A. et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm (2008) 5 e1 e6.
39. Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation (CASCADE Study). Am. J. Cardiol. (1993) 72 280 287.
40. Hoy S.M., Keam S.J. Dronedarone. Drugs (2009) 69 1647 1663.
41. Mirowski M., Reid P.R., Mower M.M. et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N. Engl. J. Med. (1980) 303 322 324.
42. Sutton R., Fisher J.D., Linde C., Benditt D.G. History of electrical therapy for the heart. Eur. Heart J. Suppl. (2007) 9 I3 I10.
43. Boriani G., Biffi M., Martignani C. et al. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM (2009) 102 349 356.
44. Leclercq C., Bleeker G.B., Linde C. et al. Cardiac resynchronization therapy: clinical results and evolution of candidate selection. Eur. Heart J. Suppl. (2007) 9 I94 I106.
45. Hohnloser S.H., Kuck K.H., Dorian P. et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J. Med. (2004) 351 2481 2488.
46. Steinbeck G., Andresen D., Seidl K. et al. Defibrillator implantation early after myocardial infarction. N. Engl. J. Med. (2009) 361 1427 1436.
47. Reddy V.Y., Reynolds M.R., Neuzil P. et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N. Engl. J. Med. (2007) 357 2657 2665.
48. Kuck K.H., Schaumann A., Eckardt L. et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet (2010) 375 31 40.
49. Viana-Tejedor A., Merino J.L., Pérez-Silva A. et al. Effectiveness of catheter ablation of ventricular tachycardia in elderly patients with structural heart disease. Rev. Esp. Cardiol. (2010) 63 156 160.
50. CIBIS Investigators. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 90 1765 1773.
51. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353 9 13.
52. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353 2001 2007.
53. The beta-blocker evaluation of survival trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. (2001) 344 1659 1667.
54. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357 1385 1390.
55. Paker M., Coast A.J., Flower M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344 1651 1658.
56. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362 7 13.
57. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98 1184 1191.
58. Freemantle N., Cleland J., Young P., Manson J., Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (1999) 318 1730 1737.
59. Brophy J.M., Joseph L., Roleau J.L. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann. Intern. Med. (2001) 134 550 560.
60. Alberte C., Zipes D.P. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J. Cardiovasc. Electrophysiol. (2003) 9 (Suppl) S87 S95.
61. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. (1987) 316 1429 1435.
62. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. (1991) 325 293 302.
63. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. (1992) 327 685 691.
64. Cohn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. (1991) 325 303 310.
65. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. (1992) 327 669 677.
66. The AIRE investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet (1993) 342 821 828.
67. The GISSI-3 investigators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet (1994) 343 1115 1122.
68. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. (1995) 332 80 85.
69. Kober L., Torp-Pedersen C., Carlsen J.E. et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. (1995) 333 1670 1676.
70. The ISIS-4 investigators. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet (1995) 345 669 685.
71. Tusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342 145 153.
72. Teo K.K., Mitchell L.B., Pogue J. et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation (2004) 110 1413 1417.
73. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362 782 788.
74. Braunwald E., Domanski M.I., Fowler S.E. et al. Angiotensin-converting- enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. (2004) 351 2058 2068.
75. Domanski M.I., Exner D.V., Borkowf C.B., Gellar N.L., Rosenberg Y., Pfeffer M.A. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1999) 33 598 604.
76. Flather M.D., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355 1575 1581.
77. Dagenais G.R., Pogue J., Fox K., Simoons Ml., Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 368 581 588.
78. Al-Mallah M.H., Tleyjeh I.M., Abdel-Latif A.A., Weaver W.D. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2006) 47 1576 1583.
79. Danchin N., Cucherat M., Thuillez C., Durand E., Kadri Z., Steg P.G. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch. Intern. Med. (2006) 166 787 796.
80. Pitt B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349 747 752.
81. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355 1582 1587.
82. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345 1667 1675.
83. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360 752 760.
84. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359 995 1003. (Pubitemid 34286536)
85. Pfeffer M.A., Mcmurray J.I., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349 1893 1906.
86. Young J.B., Dunlap M.E., Pfeffer M.A. et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 110 2618 2626.
87. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. (2008) 358 1547 1559.
88. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin converting enzyme inhibitors: a randomised controlled trial. Lancet (2008) 372 1174 1183.
89. Jong P., Demers C., Mckelvie R.S., Liu P.P. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2002) 39 463 470. (Pubitemid 34117504)
90. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein G.D., Weingarten S.R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann. Intern. Med. (2004) 141 693 704.
91. Scandinavian simvastatin survival study group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344 1383 1389.
92. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333 1301 1307.
93. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335 1001 1009.
94. The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339 1349 1357.
95. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279 1615 1622.
96. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285 1711 1718.
97. Heart protection study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7 22.
98. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360 1623 1630.
99. ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288 2998 3007.
100. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361 1149 1158. (Pubitemid 36398384)
101. Thompson P.L., Meredith I., Amerena J. et al. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am. Heart J. (2004) 148 e2.
102. Cannon C.P., Braunwald E., Mccabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350 1495 1504.
103. Larosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352 1425 1435.
104. CORONA Group Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. (2007) 357 2248 2261.
105. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 372 1231 1239.
106. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. (2008) 359 2195 2207.
107. Vrecer M., Turk S., Drinovec J., Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int. J. Clin. Pharmacol. Ther. (2003) 41 567 577.
108. Cheung B.M., Lauder I.J., Lau C.P., Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. (2004) 57 640 651.
109. Burr M.L., Fehily A.M., Gilbert J.F. et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 2 757 761.
110. Singh R.B., Niaz M.A., Sharma J.P., Kumar R., Rastogi V., Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival - 4. Cardiovasc. Drugs Ther. (1997) 11 485 491.
111. De Lorgeril M., Salen P., Martin J.L., Monjaud I., Delaye J., Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation (1999) 99 779 785.
112. GISSI-prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (1999) 354 447 455.
113. Wang C., Harris W.S., Chung M. et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. (2006) 84 5 17.
114. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am. J. Clin. Nutr. (2008) 87 1991S 1996S.
115. Brouwer I.A., Zock P.L., Camm A.J. et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA (2006) 295 2613 2619.
116. Zhao Y.T., Chen Q., Sun Y.X. et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann. Med. (2009) 41 301 310.
117. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341 709 717.
118. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348 1309 1321.
119. Micromedex Thomson® Healthcare system DRUGDEX® evaluations, available at http://www.thomsonhc.com (last access 15/03/2010).
120. Mason R.P., Giles T.D., Sowers J.R. Evolving mechanisms of action of beta blockers: focus on nebivolol. J. Cardiovasc. Pharmacol. (2009) 54 123 128.
121. Burnier M. Angiotensin II type 1 receptor blockers. Circulation (2001) 103 904 912.
122. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84 413 428.
123. Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 23 (Suppl 1) III50 III57.